<sup>18</sup>F-FDG PET用于肿瘤治疗疗效评价的meta分析进展

王玉婷; 黄钢; 蒋瑾; 陈加源; 王玉婷; 黄钢; 蒋瑾; 陈加源

doi:10.3760/cma.j.issn.1673-4114.2012.06.004

[1]

Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant pacli-taxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol, 2008, 26(31):5043-5051. doi: 10.1200/JCO.2008.16.4855

[2]

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua-tion criteria in solid tumours:revised RECIST guideline(version 1. 1). Eur J Cancer, 2009, 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026

[3]

Weber WA. Assessing tumor response to therapy. J Nucl Med, 2009, 50 Suppl1:1S-10.

[4]

Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography(PET) alone on expected management of patients with cancer:initial results from the National Oncologic PET Registry. J Clin Oncol, 2008, 26(13):2155-2161. doi: 10.1200/JCO.2007.14.5631

[5]

Therasse P, Eisenhauer EA, Verweij J. RECIST revisited:a review of validation studies on tumour assessment. Eur J Cancer, 2006, 42(8):1031-1039. doi: 10.1016/j.ejca.2006.01.026

[6]

Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors. J Nucl Med, 2009, 50 Suppl1:122S-150.

[7]

Hutchings M, Barrington SF. PET/CT for therapy response assess-ment in lymphoma. J Nucl Med, 2009, 50 Suppl1:21S-30.

[8]

Zinzani PL, Gandolfi L, Broccoli A, et al. Midtreatment ¹⁸F-fluo-rodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer, 2011, 117(5):1010-1018. doi: 10.1002/cncr.25579

[9]

Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007, 25(5):579-586. doi: 10.1200/JCO.2006.09.2403

[10]

Ramos-Font C, Rebollo Aguirre AC, Villegas Portero R, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis. Rev Esp Med Nucl, 2009, 28(2):48-55. doi: 10.1016/S0212-6982(09)70696-2

[11]

Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. ¹⁸F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma:a systematic review. Haemato-logica, 2006, 91(4):522-529.

[12]

Terasawa T, Nihashi T, Hotta T, et al. ¹⁸F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma:a systematic review. J Nucl Med, 2008, 49(1):13-21.

[13]

Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglu-cose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma:a systematic review and meta-analysis. Oncologist, 2010, 15(7):750-759. doi: 10.1634/theoncologist.2010-0054

[14]

Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, et al. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol, 2010, 101(6):486-494. doi: 10.1002/jso.21525

[15]

Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med, 2009, 50 Suppl1:55S-63.

[16]

Wang Y, Zhang C, Liu J, et al. Is ¹⁸F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat, 2012, 131(2):357-369. doi: 10.1007/s10549-011-1780-z

[17]

Cheng X, Li Y, Liu B, et al. ¹⁸F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer:a meta-analysis. Acta Radiol, 2012, 53(6):615-627. doi: 10.1258/ar.2012.110603

[18]

Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treat-ment of locally advanced esophageal cancer:a systematic review and decision analysis. Ann Thorac Surg, 2007, 83(4):1257-1264. doi: 10.1016/j.athoracsur.2006.11.061

[19]

Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, et al. ¹⁸F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer:systematic review of the literature. Ann Surg, 2009, 250(2):247-254. doi: 10.1097/SLA.0b013e3181b0c3a6

[20]

Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer:CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology, 2005, 236(3):841-851.

[21]

Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med, 2012, 53(6):872-880. doi: 10.2967/jnumed.111.098699

[22]

Suttie SA, Welch AE, Park KG. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. Eur J Surg Oncol, 2009, 35(10):1019-1029. doi: 10.1016/j.ejso.2009.01.012

[23]

Neuman HB, Elkin EB, Guillem JG, et al. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy:a decision analysis. Dis Colon Rectum, 2009, 52(5):863-871. doi: 10.1007/DCR.0b013e31819eefba

[24]

Zhang C, Tong J, Sun X, et al. ¹⁸F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer:a meta-analysis. Int J Cancer, 2012, 131(11):2604-2611. doi: 10.1002/ijc.27557

[25]

Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using[¹⁸F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recom-mendations. European Organization for Research and Treatment of Cancer(EORTC) PET Study Group. Eur J Cancer, 1999, 35(13):1773-1782. doi: 10.1016/S0959-8049(99)00229-4

[26]

Treglia G, Mirk P, Stefanelli A, et al. ¹⁸F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors:a sys-tematic review. Clin Imaging, 2012, 36(3):167-175. doi: 10.1016/j.clinimag.2011.08.012

[27]

Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET:conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer, 2010, 102(1):35-41. doi: 10.1038/sj.bjc.6605427

[28]

Park JS, Moon WK, Lyou CY, et al. The assessment of breast cancer response to neoadjuvant chemotherapy:comparison of magnetic resonance imaging and ¹⁸F-fluorodeoxyglucose positron emission tomography. Acta Radiol, 2011, 52(1):21-28.